Abstract
Multiple sclerosis (MS)-related spasticity is associated with disability and impairment in quality of life. We report on a patient with secondary progressive MS and spastic tetraparesis (Expanded Disability Status Scale score 8.5). The right arm exhibited flexor spasticity resulting in functional disability despite multimodal symptomatic treatment. Intrathecal baclofen led to side effects despite decreasing efficacy. Low-dose nabiximols improved spasticity and function with recovery of daily-life activities and spasticity-related symptoms. Reduction of intrathecal baclofen ameliorated adverse drug reactions. Add-on cannabinoid therapy was effective in therapy-refractory spasticity with supra-additive effect in combining intrathecal baclofen and nabiximols, hypothetically explained by mutually complementing mechanisms of action.
| Original language | English |
|---|---|
| Pages (from-to) | 199-203 |
| Number of pages | 5 |
| Journal | Therapeutic Advances in Neurological Disorders |
| Volume | 6 |
| Issue number | 3 |
| DOIs | |
| State | Published - May 2013 |
| Externally published | Yes |
Keywords
- CB1 receptor
- cannabinoids
- multiple sclerosis
- nabiximols
- secondary progressive multiple sclerosis
- spastic tetraparesis
- symptomatic treatment